Does Rallies show Form 4 insider transactions for LUNG?

Yes. Rallies tracks LUNG insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is LUNG research on Rallies investment advice?

No. Rallies provides research, data, and educational context for LUNG. It does not provide personalized investment advice.

LUNG (Pulmonx Corporation Common Stock) Stock Analysis - Insider Trades

Pulmonx Corporation Common Stock (LUNG) is a publicly traded Healthcare sector company. As of May 21, 2026, LUNG trades at $1.53 with a market cap of $55.33M and a P/E ratio of -1.16. LUNG moved +15.67% today. Year to date, LUNG is -31.25%; over the trailing twelve months it is -54.03%. Its 52-week range spans $1.13 to $9.37. Analyst consensus is strong buy with an average price target of $3.50. Rallies surfaces LUNG's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading LUNG stock inside the company?

Recent LUNG insider activity includes Radhakrishnan Srikanth sold 756, Radhakrishnan Srikanth sold 3.07K, Radhakrishnan Srikanth sold 2.46K, Radhakrishnan Srikanth sold 4.20K, and French Glendon E. III sold 2.71K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

LUNG Key Metrics

Key financial metrics for LUNG
Metric	Value
Price	$1.53
Market Cap	$55.33M
P/E Ratio	-1.16
EPS	$-1.30
Dividend Yield	0.00%
52-Week High	$9.37
52-Week Low	$1.13
Volume	0
Avg Volume	0
Revenue (TTM)	$88.55M
Net Income	$-53.21M
Gross Margin	75.49%

Recent LUNG Insider Trades

Radhakrishnan Srikanth sold 756 (~$1.08K) on Mar 2, 2026.
Radhakrishnan Srikanth sold 3.07K (~$4.39K) on Mar 2, 2026.
Radhakrishnan Srikanth sold 2.46K (~$3.52K) on Mar 2, 2026.
Radhakrishnan Srikanth sold 4.20K (~$6.00K) on Mar 2, 2026.
French Glendon E. III sold 2.71K (~$3.87K) on Mar 2, 2026.

Latest LUNG News

Pulmonx Q1 Revenue Drops 9% to $20.6M, Margin Rises to 78% — Apr 29, 2026
Pulmonx Cuts Expenses Over 10% and Forecasts $90–92M Revenue in 2026 — Mar 5, 2026
Pulmonx Reports $0.25 EPS Loss, Beats Revenue by 3.97%, Shares Down 30.8% — Mar 4, 2026
Pulmonx Posts 8% Revenue Growth to $90.5M, Secures $60M Five-Year Loan — Mar 4, 2026

LUNG Analyst Consensus

4 analysts cover LUNG: 0 strong buy, 3 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $3.50.

Common questions about LUNG

Who is trading LUNG stock inside the company?: Recent LUNG insider activity includes Radhakrishnan Srikanth sold 756, Radhakrishnan Srikanth sold 3.07K, Radhakrishnan Srikanth sold 2.46K, Radhakrishnan Srikanth sold 4.20K, and French Glendon E. III sold 2.71K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for LUNG?: Yes. Rallies tracks LUNG insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is LUNG research on Rallies investment advice?: No. Rallies provides research, data, and educational context for LUNG. It does not provide personalized investment advice.